What is the recommended dosing of Augmentin (amoxicillin/clavulanate) for a patient with impaired renal function, specifically stage 3b kidney disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Augmentin Dosing in Stage 3b Chronic Kidney Disease

For patients with CKD stage 3b (GFR 30-44 mL/min), reduce Augmentin to 375 mg twice daily instead of the standard three times daily dosing to prevent drug accumulation and toxicity. 1

Rationale for Dose Adjustment

Stage 3b CKD represents moderate to severe renal impairment with GFR between 30-44 mL/min, which significantly affects the elimination of both amoxicillin and clavulanic acid components of Augmentin. 1

Pharmacokinetic Considerations

  • Both amoxicillin and clavulanic acid are primarily renally cleared, making dose adjustment essential in renal impairment to avoid accumulation. 2

  • In patients with end-stage renal disease, the total serum clearance of both components is substantially reduced compared to patients with normal renal function, demonstrating the critical impact of kidney function on drug elimination. 2

  • The terminal half-life of amoxicillin increases dramatically from approximately 1 hour in normal patients to 13.6 hours in severe renal impairment, while clavulanic acid half-life increases to 3.05 hours. 2

Specific Dosing Protocol

Standard dose reduction: Augmentin 375 mg (or 500/125 mg formulation) twice daily for GFR 30-44 mL/min. 1

Additional Considerations for More Severe Impairment

  • If GFR falls below 30 mL/min, further dose reduction or extended interval dosing becomes necessary. 1

  • Dosage adjustments should be calculated based on creatinine clearance or GFR using validated calculators rather than manual estimation. 3

Clinical Monitoring

  • Renal function should be monitored before initiating therapy and periodically during treatment, as drug dosing errors are common in patients with renal impairment and can lead to adverse effects. 3

  • The risk of drug accumulation increases with declining renal function, potentially causing toxicity if standard dosing is maintained. 4

Common Pitfall to Avoid

Do not use standard three-times-daily dosing in stage 3b CKD patients, as this will lead to excessive drug accumulation given the prolonged half-lives of both amoxicillin and clavulanic acid in renal impairment. 2 The reduced clearance affects not only renal excretion but also nonrenal clearance mechanisms, making dose adjustment critical even though some hepatic metabolism occurs. 2

References

Guideline

Augmentin Dosing for CKD Stage IIIb Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

European journal of clinical pharmacology, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.